175 related articles for article (PubMed ID: 2576957)
1. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma.
Sandrock D; Blossey HC; Steinroeder M; Munz DL
Henry Ford Hosp Med J; 1989; 37(3-4):173-4. PubMed ID: 2576957
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.
Troncone L; Rufini V; De Rosa G; Testa A
Henry Ford Hosp Med J; 1989; 37(3-4):178-84. PubMed ID: 2576959
[TBL] [Abstract][Full Text] [Related]
3. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
[TBL] [Abstract][Full Text] [Related]
4. Detection of metastatic medullary thyroid cancer with 131I-MIBG scans in Sipple's syndrome.
Itoh H; Sugie K; Toyooka S; Kawase M; Mukaino S; Hazama F; Endo K; Torizuka K; Nakao K; Imura H
Eur J Nucl Med; 1986; 11(12):502-4. PubMed ID: 2874028
[TBL] [Abstract][Full Text] [Related]
5. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine.
Ansari AN; Siegel ME; DeQuattro V; Gazarian LH
J Nucl Med; 1986 Dec; 27(12):1858-60. PubMed ID: 2878066
[TBL] [Abstract][Full Text] [Related]
6. [The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Sasaki Y; Kubo A; Kusakabe K; Masaki H; Endo K; Yamashita M; Nakajo M; Kaneko M
Kaku Igaku; 1992 Sep; 29(9):1083-98. PubMed ID: 1360549
[TBL] [Abstract][Full Text] [Related]
7. [Clinical applications of 131I-meta iodobenzylguanidine (131I-MIBG) scintigraphy in Japan].
Izumi M; Kakezono F; Nagayama Y; Kiriyama T; Yokoyama N; Yamashita S; Morita S; Hirayu H; Kubo I; Ohtakara S
Kaku Igaku; 1986 Feb; 23(2):145-52. PubMed ID: 2872353
[No Abstract] [Full Text] [Related]
8. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
9. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
[TBL] [Abstract][Full Text] [Related]
10. Localization of metastases from medullary thyroid carcinoma using different methods.
Cabezas RC; Berna L; Estorch M; Carrio I; Garcia-Ameijeiras A
Henry Ford Hosp Med J; 1989; 37(3-4):169-72. PubMed ID: 2639132
[TBL] [Abstract][Full Text] [Related]
11. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma.
Vuillez JP; Peltier P; Caravel JP; Chetanneau A; Saccavini JC; Chatal JF
J Clin Endocrinol Metab; 1992 Jan; 74(1):157-63. PubMed ID: 1727816
[TBL] [Abstract][Full Text] [Related]
12. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Zagar I; Han R; Mitrovic S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.
Shapiro B; Copp JE; Sisson JC; Eyre PL; Wallis J; Beierwaltes WH
J Nucl Med; 1985 Jun; 26(6):576-85. PubMed ID: 2860214
[TBL] [Abstract][Full Text] [Related]
14. Immunoscintigraphy in medullary thyroid cancer using an 123I- or 111In-labelled monoclonal anti-CEA antibody fragment.
Reiners C; Eilles C; Spiegel W; Becker W; Börner W
Nuklearmedizin; 1986 Dec; 25(6):227-31. PubMed ID: 3808964
[TBL] [Abstract][Full Text] [Related]
15. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
16. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: a case report.
O'Driscoll CM; Baker F; Casey MJ; Duffy GJ
J Nucl Med; 1991 Dec; 32(12):2281-3. PubMed ID: 1744716
[TBL] [Abstract][Full Text] [Related]
17. Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma.
Hilditch TE; Connell JM; Elliot AT; Murray T; Reed NS
J Nucl Med; 1986 Jul; 27(7):1150-3. PubMed ID: 3014086
[TBL] [Abstract][Full Text] [Related]
18. Early diagnosis of and surgical strategy for adrenal medullary disease in MEN II gene carriers.
Jansson S; Tisell LE; Fjälling M; Lindberg S; Jacobsson L; Zachrisson BF
Surgery; 1988 Jan; 103(1):11-8. PubMed ID: 2892276
[TBL] [Abstract][Full Text] [Related]
19. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma.
Manil L; Boudet F; Motte P; Gardet P; Saccavini JC; Lumbroso JD; Schlumberger M; Caillou B; Bazin JP; Ricard M
Cancer Res; 1989 Oct; 49(19):5480-5. PubMed ID: 2766309
[TBL] [Abstract][Full Text] [Related]
20. [The evaluation of 123I-MIBG scintigraphy in medullary thyroid carcinoma (MTC)].
Ahuja S; Koppenhagen K; Ernst H
Strahlenther Onkol; 1990 Nov; 166(11):718-21. PubMed ID: 2260009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
